Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Cerecor Inc (CERC) USD0.001

Sell:$4.40 Buy:$4.44 Change: $0.22 (5.26%)
NASDAQ:0.73%
Market closed |  Prices as at close on 12 December 2019 | Switch to live prices |
Sell:$4.40
Buy:$4.44
Change: $0.22 (5.26%)
Market closed |  Prices as at close on 12 December 2019 | Switch to live prices |
Sell:$4.40
Buy:$4.44
Change: $0.22 (5.26%)
Market closed |  Prices as at close on 12 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Company owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson's disease and pathological gambling. Its COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT.

Contact details

Address:
540 Gaither Rd Ste 400
ROCKVILLE
20850-6713
United States
Telephone:
+1 (410) 5228707
Website:
www.cerecor.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CERC
ISIN:
US15671L1098
Market cap:
$169.37 million
Shares in issue:
44.11 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Simon Pedder
    Executive Chairman of the Board
  • Mike Cola
    Chief Executive Officer
  • Joseph Miller
    Chief Financial Officer, Principal Executive Officer and Principal Financial Officer
  • Jamie Harrell
    Executive Vice President of Marketing, External Communications, Chief Commercial Officer
  • Pericles Calias
    Chief Scientific Officer and Head of Research & Development
  • Patrick Crutcher
    Chief Strategy Officer
  • Garry Neil
    Chief Medical Officer
  • Matthew Phillips
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.